Boston Scientific Corpora... (BSX)
Boston Scientific Corporation (BSX) Stock Price, Analysis & Data
| Cours acheteur | n/a |
| Capitalisation boursière | 74.53B |
| Chiffre d’affaires (ttm) | 21B |
| Résultat net (ttm) | 3.67B |
| Bêta | 0.57 |
| EPS (ttm) | 2.45 |
| Ratio P/E (ttm) | 20.99 |
| P/E prévisionnel | 14.96 |
| P/B (ttm) | 2.98 |
| P/S (ttm) | 3.55 |
| Earnings Date | Oct 28, 2026 |
| Cours vendeur | n/a |
| Volume | 12,903,637 |
| Volume moy. (20D) | 21,006,829 |
| Ouverture | 51.71 |
| Clôture précédente | 51.83 |
| Fourchette du jour | 51.24 - 52.06 |
| Intervalle de 52 semaines | 42.20 - 109.50 |
| Analyste | Buy |
| Objectif de prix | 60 (16.66%) |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and the...
Performance financière
En 2025, le chiffre d’affaires de Boston Scientific s’élevait à 20.07B, soit une hausse de 19.87% par rapport aux 16.75B de l’année précédente. Le bénéfice s’élevait à 2.9B, soit une hausse de 56.31%.
États financiersPrévisions des analystes
Selon les évaluations de 29 analystes, la note moyenne de l’action BSX est « Buy ». L’objectif de cours moyen à 12 mois est de 60, soit une hausse de 16.66 % par rapport au dernier cours.
Prévisions boursièresSurprise sur les résultats
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
14 heures il y a · Insider Monkey
Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device FranchisesAristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in t...
3 jours il y a · Simply Wall St.
Boston Scientific (BSX), What Is Behind The Latest Investor Attention?Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2...
3 jours il y a · Simply Wall St.
Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while...
